Signal Genetics Taps NeoGenomics to Market Array-Based Myeloma Test to US Hospitals
May 31, 2011
Signal Genetics Taps NeoGenomics to Market Array-Based Myeloma Test to US Hospitals
Startup Signal Genetics has decided to partner with specialty labs that have existing relationships with its target market instead of creating its own sales organization.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Signal Genetics to Buy ChipDx, Gaining Cancer Test Pipeline, Bioinformatics Resources
February 7, 2012 / BioArray News - Signal Genetics Plans to Release Pharmacogenomic Version of Myeloma Test Later This Year
June 1, 2011 / Pharmacogenomics Reporter - BioMerieux to Move Array-Based Tests to Biocartis, Other MDx Platforms
March 29, 2011 / BioArray News - Despite Genotyping Growth, Affymetrix's Q3 Sales Fall 5 Percent on Service Slowdown
November 2, 2010 / BioArray News - Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs
September 21, 2010 / BioArray News